Company: MLTX
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001140361-25-014923
Chunk: 50

Company: MoonLake Immunotherapeutics
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 50
---
 13G filed on February 14, 2025 and consists of 3,343,643 Class A Ordinary Shares. As investment advisor, T. Rowe Price Associates, Inc. (“Price Associates”) holds sole voting power over 3,309,301 shares and sole dispositive power over 3,343,643 shares. Price Associates disclaims beneficial ownership of the shares. The business address Price Associates is 100 East Pratt Street, Baltimore, Maryland 21202. |

Securities Authorized for Issuance Under Equity Compensation Plans The following table contains information about our equity compensation plans as of December 31, 2024. As of December 31, 2024, we had outstanding awards under the Incentive Plan, as well as outstanding awards under the MoonLake AG Amended and Restated Stock Option Plan (“ESOP”) and the ESPP as described below.

| Plan Category                                              |     | Number of Securities 
    to Be Issued Upon 
          Exercise of 
 Outstanding Options, 
  Warrants and Rights 
                  (a) |     |     Weighted-Average 
    Exercise Price of 
 Outstanding Options, 
  Warrants and Rights 
                  (b) |     |     Number of Securities 
      Remaining Available 
      for Future Issuance 
             Under Equity 
       Compensation Plans 
    (Excluding Securities 
 Reflected in Column (a)) 
                      (c) |
| Equity compensation plans approved by security holders     |     |         1,912,140(1) |     |            $22.79(2) |     |             3,283,077(3) |
| Equity compensation plans not approved by security holders |     |                    — |     |                    — |     |                        — |
| Total                                                      |     |            1,912,140 |     |               $22.79 |     |                3,283,077 |

| (1) | Includes (i) 972,478 share options granted under the Incentive Plan; (ii) 2,925 shares of MoonLake AG subject to options granted under the ESOP which may ultimately be converted into 98,393 MoonLake Immunotherapeutics Class A Ordinary Shares issuable under the Incentive Plan and (iii) 25,009 shares of MoonLake AG purchased under the ESPP which, together with 841,269 MoonLake Immunotherapeutics Class C Ordinary Shares, may ultimately be converted into 841,269 MoonLake Immun